Prelude Therapeutics: Dr. Krishna Vaddi Holds 10% Stake

Ticker: PRLD · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1678660

Complexity: simple

Sentiment: bullish

Topics: insider-ownership, amendment, biotech, pharmaceuticals

TL;DR

**Insider Dr. Vaddi owns 10% of Prelude Therapeutics, signaling strong confidence.**

AI Summary

Dr. Krishna Vaddi, a key figure at Prelude Therapeutics Inc., filed an amended SC 13G/A on February 12, 2024, disclosing his beneficial ownership of 4,908,086 shares of the company's common stock as of December 31, 2023. This represents a significant 10.0% stake in the pharmaceutical company. This filing is important for investors as it shows a substantial insider holding, which can signal confidence in the company's future, especially for a biotech firm like Prelude Therapeutics (NASDAQ: PRLD) that relies heavily on its leadership's vision.

Why It Matters

High insider ownership, like Dr. Vaddi's 10% stake, often indicates that company leadership believes in the long-term prospects, aligning their interests with shareholders.

Risk Assessment

Risk Level: low — This filing indicates a significant insider stake, which generally reduces perceived risk due to aligned interests between management and shareholders.

Analyst Insight

A smart investor would view this significant insider ownership as a positive signal, suggesting strong conviction from a key executive, and might consider further research into Prelude Therapeutics' pipeline and financials.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

Who is the reporting person in this SC 13G/A filing?

The reporting person in this SC 13G/A filing is Krishna Vaddi, as stated on the cover page and Item 1 of the Schedule 13G.

What is the name of the issuer whose securities are being reported?

The issuer of the securities is Prelude Therapeutics Incorporated, as identified in the 'Name of Issuer' section of the Schedule 13G/A.

How many shares of Prelude Therapeutics Inc. common stock does Krishna Vaddi beneficially own?

Krishna Vaddi beneficially owns 4,908,086 shares of Prelude Therapeutics Inc. common stock, as detailed in Item 5 of the Schedule 13G.

What percentage of the class of securities does Krishna Vaddi's ownership represent?

Krishna Vaddi's ownership represents 10.0% of the class of securities, as stated in Item 9 of the Schedule 13G.

What was the 'Date of Event Which Requires Filing of this Statement' for this amendment?

The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as indicated on the cover page of the Schedule 13G/A.

Filing Stats: 1,159 words · 5 min read · ~4 pages · Grade level 9.4 · Accepted 2024-02-12 16:26:50

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 12, 2024 By: /s/ Krishna Vaddi Krishna Vaddi

View Full Filing

View this SC 13G/A filing on SEC EDGAR

View on Read The Filing